Colgate DCF Signals Overvaluation Despite Moat

What happened

On June 24, 2026, a DCF analysis from GuruFocus pegged Colgate-Palmolive's intrinsic value at $43 per share, sharply below its $91 trading price, highlighting extreme overvaluation. Meanwhile, the DeepValue master report's base-case DCF of $65.46 and a Hold rating already warned of a negative margin of safety at $76.98. The stock's further 18% climb since the report underscores worsening risk/reward, even though Colgate's durable 41.4% toothpaste share and strong cash generation ($4.1B OCF in 2024) support the franchise. However, Q2 2025 results show flat volumes, North America operating profit down 9%, and persistent FX headwinds, indicating growth challenges. The new DCF update amplifies concerns that the market is pricing in unrealistic growth assumptions beyond what the conservative base case allows.

Implication

The GuruFocus DCF amplifies the overvaluation identified in the DeepValue report. At $91, the stock trades at 2.1x the $43 intrinsic value and 1.4x the $65.46 base-case DCF. Investors should consider reducing positions or waiting for a pullback closer to intrinsic value. The wide dispersion between the two DCFs (43 vs 65) highlights high uncertainty in terminal value assumptions, but both point to significant downside. The Hold thesis remains intact, but the risk/reward has deteriorated further.

Thesis delta

The new DCF analysis lowers the intrinsic value estimate dramatically from the report's $65.46 to $43, suggesting the stock is even more overvalued than previously thought. This reinforces the negative margin of safety and increases the likelihood of mean reversion. The thesis shifts from cautious Hold to a more bearish stance, as the upside from moat and buybacks is insufficient to justify the current price.